Home LiteratureArticle Details
PMID: 26627015 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.

Cancer research ·Vol. 75 ·No. 24 ·2015-12-15 ·页码 5228-34

Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM, Fellowes A, Leonard JH, Hruby G, Mann GJ, Thompson JF, Cullinane C, Johnston M, Shackleton M, Sandhu S, Bowtell DD, Johnstone RW, Fox SB, McArthur GA, Papenfuss AT, Scolyer RA, Gill AJ, Hicks RJ, Tothill RW

Abstract

Merkel cell carcinoma (MCC) is an uncommon, but highly malignant, cutaneous tumor. Merkel cell polyoma virus (MCV) has been implicated in a majority of MCC tumors; however, viral-negative tumors have been reported to be more prevalent in some geographic regions subject to high sun exposure. While the impact of MCV and viral T-antigens on MCC development has been extensively investigated, little is known about the etiology of viral-negative tumors. We performed targeted capture and massively parallel DNA sequencing of 619 cancer genes to compare the gene mutations and copy number alterations in MCV-positive (n = 13) and -negative (n = 21) MCC tumors and cell lines. We found that MCV-positive tumors displayed very low mutation rates, but MCV-negative tumors exhibited a high mutation burden associated with a UV-induced DNA damage signature. All viral-negative tumors harbored mutations in RB1, TP53, and a high frequency of mutations in NOTCH1 and FAT1. Additional mutated or amplified cancer genes of potential clinical importance included PI3K (PIK3CA, AKT1, PIK3CG) and MAPK (HRAS, NF1) pathway members and the receptor tyrosine kinase FGFR2. Furthermore, looking ahead to potential therapeutic strategies encompassing immune checkpoint inhibitors such as anti-PD-L1, we also assessed the status of T-cell-infiltrating lymphocytes (TIL) and PD-L1 in MCC tumors. A subset of viral-negative tumors exhibited high TILs and PD-L1 expression, corresponding with the higher mutation load within these cancers. Taken together, this study provides new insights into the underlying biology of viral-negative MCC and paves the road for further investigation into new treatment opportunities.

MeSH 主题词
Blotting, Western Carcinoma, Merkel Cell/genetics Cells, Cultured DNA Damage/radiation effects DNA Mutational Analysis High-Throughput Nucleotide Sequencing Humans Immunohistochemistry Merkel cell polyomavirus Mutation Polymerase Chain Reaction Skin Neoplasms/genetics Transcriptome Ultraviolet Rays/adverse effects
作者与单位
共 30 位作者,点击展开单位 / ORCID
Wong Stephen Q
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Waldeck Kelly
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Vergara Ismael A
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Schröder Jan
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Walter Eliza Hall Institute, Melbourne, Victoria, Australia. Department of Computing and Information Systems, University of Melbourne, Melbourne, Victoria, Australia.
Madore Jason
Melanoma Institute Australia and the University of Sydney, Sydney, New South Wales, Australia.
Wilmott James S
Melanoma Institute Australia and the University of Sydney, Sydney, New South Wales, Australia.
Colebatch Andrew J
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Department of Pathology, University of Melbourne, Melbourne, Victoria, Australia.
De Paoli-Iseppi Ricardo
Melanoma Institute Australia and the University of Sydney, Sydney, New South Wales, Australia.
Li Jason
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Lupat Richard
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Semple Timothy
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Arnau Gisela Mir
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Fellowes Andrew
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Leonard J Helen
QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Hruby George
Melanoma Institute Australia and the University of Sydney, Sydney, New South Wales, Australia.
Mann Graham J
Melanoma Institute Australia and the University of Sydney, Sydney, New South Wales, Australia.
Thompson John F
Melanoma Institute Australia and the University of Sydney, Sydney, New South Wales, Australia.
Cullinane Carleen
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Johnston Meredith
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Shackleton Mark
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Sandhu Shahneen
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Bowtell David D L
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Department of Pathology, University of Melbourne, Melbourne, Victoria, Australia. The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Johnstone Ricky W
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Fox Stephen B
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Department of Pathology, University of Melbourne, Melbourne, Victoria, Australia. The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
McArthur Grant A
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Papenfuss Anthony T
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Walter Eliza Hall Institute, Melbourne, Victoria, Australia. The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia. Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
Scolyer Richard A
Melanoma Institute Australia and the University of Sydney, Sydney, New South Wales, Australia.
Gill Anthony J
Cancer Diagnosis and Pathology Research Group Kolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.
Hicks Rodney J
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
Tothill Richard W
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Department of Pathology, University of Melbourne, Melbourne, Victoria, Australia. richard.tothill@petermac.org.
Article Info
Journal
Cancer research
Abbr.
Cancer Res
ISSN
1538-7445
Corresponding email
Published
2015-12-15
电子出版
2015-00-01
页码
5228-34
Language
English
Country/Region
United States
NLM ID
2984705R
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com